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ABSTRACT
Alternative pre-messenger RNA splicing remodels
the human transcriptome in a spatiotemporal
manner during normal development and differenti-
ation. Here we explored the landscape of transcript
diversity in the erythroid lineage by RNA-seq
analysis of five highly purified populations of
morphologically distinct human erythroblasts, rep-
resenting the last four cell divisions before enucle-
ation. In this unique differentiation system, we found
evidence of an extensive and dynamic alternative
splicing program encompassing genes with many
diverse functions. Alternative splicing was particu-
larly enriched in genes controlling cell cycle,
organelle organization, chromatin function and
RNA processing. Many alternative exons exhibited
differentiation-associated switches in splicing effi-
ciency, mostly in late-stage polychromatophilic
and orthochromatophilic erythroblasts, in concert
with extensive cellular remodeling that precedes
enucleation. A subset of alternative splicing
switches introduces premature translation termin-
ation codons into selected transcripts in a differen-
tiation stage-specific manner, supporting the
hypothesis that alternative splicing-coupled
nonsense-mediated decay contributes to regulation
of erythroid-expressed genes as a novel part of the
overall differentiation program. We conclude that a
highly dynamic alternative splicing program in
terminally differentiating erythroblasts plays a
major role in regulating gene expression to ensure
synthesis of appropriate proteome at each stage as
the cells remodel in preparation for production of
mature red cells.
INTRODUCTION
Alternative pre-messenger RNA (mRNA) splicing enables
individual genes to generate multiple protein products that
differ structurally and functionally by insertion or deletion
of important functional domains encoded by alternative
exons. During normal development and differentiation,
dynamic changes in the expression or activity of the
splicing regulatory machinery coordinately modulate
networks of alternative splicing events in a spatiotemporal
manner. Post-transcriptional RNA processing can thereby
modulate essential protein functions according to the
physiological requirements of the cell by regulating
coherent biological pathways (1). Conversely, network
perturbations caused by mutations that alter splicing
factor expression or activity underlie an array of
complex human diseases (2). The experimental work sup-
porting these concepts has been performed primarily
in non-hematologic cell types. However, recent studies
have revealed that normal T cells execute a complex
splicing program (3) and that splicing factor mutations
are associated with hematological cancers, including
myelodysplasia (4–6), demonstrating the importance of
alternative splicing in hematology. Characterization of
the alternative splicing program in human erythroblasts
undergoing terminal erythroid differentiation will reveal
novel insights into RNA regulatory pathways that drive
cell differentiation and provide a basis for identifying
splicing defect in human erythroid diseases.
Alternative isoforms of various erythroid transcripts
have been reported, and a modest number of differenti-
ation stage-speciﬁc switches in alternative splicing patterns
are known (7). Best studied mechanistically is the upregu-
lation of splicing efﬁciency for protein 4.1R alternative
exon 16, which encodes part of the spectrin–actin
binding domain required for optimal assembly of a mech-
anically competent membrane skeleton (8,9), an essential
structure for mature erythrocyte function. This exon is
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predominantly skipped in early erythroblasts but included
efﬁciently in late erythropoiesis (10,11), and several RNA
binding proteins/splicing factors that inﬂuence exon 16
splicing have been identiﬁed (12–15). Underscoring the
importance of this splicing switch, failure to include
exon 16 causes mechanically unstable red cells and
aberrant elliptocytic phenotype with anemia (16,17).
To comprehensively explore the alternative splicing
landscape during terminal erythroid differentiation,
we used anRNA-seq strategy to analyze and compare tran-
scriptomes of highly puriﬁed human erythroblasts cultured
in vitro from CD34+cord blood progenitors (18). RNA-seq
allows a robust high-resolution assessment of the transcrip-
tome, but there remain computational challenges in data
interpretation. Using extensions of current transcript abun-
dance estimation tools combined with non-parametric stat-
istical methods, we found an extensive alternative splicing
program that is signiﬁcantly enriched in genes controlling
cell cycle, organelle organization, chromatin function and
RNA processing. Importantly, hundreds of these alterna-
tive splicing events are regulated in a differentiation stage-
speciﬁc manner, with most switches in exon inclusion/ex-
clusion efﬁciency occurring in late-stage erythroblasts con-
current with extensive cellular remodeling as erythroblasts
transition from a highly proliferative state to a terminally
differentiated state. Finally, we discovered a subset of
splicing switches that introduce premature translation ter-
mination codons (PTCs), thus decreasing the proportion of
full-length coding mRNAs and downregulating gene ex-
pression via induction of nonsense-mediated decay
(NMD). Post-transcriptional RNA processing pathways
may be regulated by this mechanism in late erythroid dif-
ferentiation, as numerous RNA binding proteins exhibit
elevated expression of PTC exons in the most mature
erythroblasts. These studies support the central hypothesis
that human erythroblasts execute a surprisingly complex,
differentiation stage-speciﬁc alternative splicing pro-
gram that is essential for normal proliferation and
differentiation.
MATERIALS AND METHODS
Human erythroblast populations
CD34+cells were enriched from cord blood, cultured under
conditions that promote erythroblast differentiation,
and further enriched for stage-speciﬁc erythroblast popula-
tions by ﬂuorescence-activated cell sorting (FACS) exactly
as described (18). By gating narrow windows, high cell
purity is attained for ﬁve discrete erythroblast populations
(>90%), representing the last four cell divisions in terminal
erythropoiesis. In some experiments, the cell populations
enriched for proerythroblasts (proE) (culture day 9) and
orthochromatic erythroblasts (orthoEs) (culture day 16)
were treated with 100mg/ml cycloheximide for 4 h to
inhibit nonsense-mediated decay of RNA transcripts con-
taining PTCs.
RNA-seq analysis
Total RNA was extracted using an RNeasy Plus Mini Kit
(QIAGEN) from sorted human erythroblasts at distinct
stages of erythroid maturation. The integrity of the
RNA was evaluated on an Agilent Bioanalyzer, and
samples with RNA integrity numbers (RIN) >8.0 were
prepared for sequencing. Poly(A)-tailed RNA was subse-
quently prepared by the Epigenomics Core, Cornell
Medical College, using the mRNA Seq Sample Prep Kit
(Illumina Inc., San Diego, CA, USA) and used to create
libraries for HiSeq2000 sequencing (Illumina).
Hundreds of millions of 50-nt RNA-seq reads were
obtained from each of the 15 erythroblast samples, repre-
senting ﬁve distinct stages of differentiation from three
independent sorting experiments. RNA-seq fragments
were aligned to the Ensembl-annotated transcriptome
version 67 (19) [hg19 human genome build GRCh37
(20)] using the Bowtie aligner (21). Read statistics are
given in Supplementary Table S1. Transcript-level esti-
mates were obtained using the transcript abundance
estimation tool, eXpress (22), and were expressed as
fragments per kilobase of exon per million fragments
mapped (FPKM) as described previously (23,24). For
each exon of every Ensembl gene, transcripts from the
gene were divided into two sets: the set of isoforms
including the exon (termed inclusion) and the set
of isoforms with an intronic region spanning it (termed
overlap). Expression of individual exons in ‘exon-
inclusion’ isoforms relative to the total expression of all
isoforms was represented as percent spliced in (PSI) and
computed by calculating the ratio FPKM (inclusion)/
FPKM (inclusion, overlap). Because only ratios of reads
were compared, a library size normalization step between
samples was not needed.
To classify exons as differentially expressed between the
proE and orthoE samples, we used the estimated PSI
values with the samr R package (25), assuming continuous
data. This resulted in a test similar to a t-test, but where
the null distribution was generated by a permutation test
non-parametrically from the data. In the same manner, we
estimated the PSI of each exon in the basophilic (basoE)
and polychromatophilic (polyE) erythroblast populations.
We then considered any exon for which the inclusion plus
overlap FPKM was in the lower quartile to be insufﬁ-
ciently expressed and discarded it from the analysis. We
also removed any exon for which a contributing isoform
had a contradiction in coverage by having long spanning
regions of 0 coverage (see Supplementary Methods). From
this list ﬁltered for low gene expression, we also ﬁltered
out exons with minimal alternative splicing (PSI <0.05 or
>0.95) at any differentiation stage, because empirically we
found that this PSI ﬁlter greatly reduced the incidence
of false positives. Data for the PSI-ﬁltered set of splicing
events are shown in Supplementary Table S2, and
the larger unﬁltered PSI data set is provided in
Supplementary Table S3. The ﬁltered list of alternatively
spliced exons was used as input into GOrilla (Gene
Ontology enRIchment anaLysis and visuaLizAtion tool)
for Gene Ontology (GO) analysis (26) (Table 1) and for
analyzing stage-speciﬁcity of splicing switches (Figure 5).
Besides the computationally deﬁned alternative splicing
switches, a few additional examples were discovered in
genes of interest by manual inspection of RNA-seq
reads mapped to the human genome. Exons that did not
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computationally meet a PSI threshold of 10% but
showed strong evidence for stage-speciﬁc changes in the
ratio of exon junction reads supporting inclusion versus
exon exclusion reads were tested by reverse-transcriptase
polymerase chain reaction (RT-PCR); examples of
splicing switches detected in this manner are MEF2D,
PICALM and MTMR3.
Validation of computationally predicted alternative exons
Many alternative splicing events were veriﬁed by manual
inspection of mapped reads on the human genome
browser, to ﬁlter out exons not supported by multiple
exon-inclusion and exon-skipping reads. In selected
cases, RT-PCR analysis was performed to visualize the
ampliﬁed products corresponding to inclusion and
skipping events. Total RNA was reverse-transcribed into
cDNA using random primers and the Superscript III First
Strand Synthesis System (Invitrogen), and PCR analysis
was performed using AccuTaq polymerase (Sigma) using
primers located in constitutive exons located upstream
and downstream of each candidate alternative exon.
Primer sequences are given in Supplementary Table S4.
For initial RT-PCR validations, RNA from unsorted
day 9 (proE-enriched) and day 16 (orthoE-enriched) cells
was used; these results were subsequently conﬁrmed with
RNA puriﬁed from highly enriched (FACS-sorted) proEs
and orthochromatophilic erythroblasts.
RESULTS
Differentiating erythroid cells execute a robust alternative
splicing program
Highly puriﬁed human erythroblasts were obtained from
in vitro cultures by FACS using differentiation stage-
restricted cell surface markers as previously described
(18). Stage-speciﬁc RNA-seq libraries were prepared
from ﬁve morphologically distinct populations of succes-
sively more differentiated erythroblasts, each separated
from the next by one cell division: proEs, early basophilic
erythroblasts (e-basoE), late basophilic erythroblasts
(l-basoE), polychromatophilic erythroblasts (polyE) and
ﬁnally orthochromatophilic erythroblasts (orthoE), the
last stage before enucleation (Figure 1). Three independ-
ent preparations of sorted cells were analyzed to provide
biological replicates.
Alternative splicing events in differentiating erythro-
blasts were identiﬁed following the strategy shown in
Figure 2. A total of 1.5 billion reads representing the tran-
scriptomes of all 15 erythroblast samples were mapped to
the Ensembl annotated transcriptome and analyzed using
numerous tools to derive exon-level alternative splicing
information as described in ‘Methods’ section. The
initial set of 243 464 candidate alternative exons was
ﬁltered to remove low-expression genes, and exons with
minimal alternative splicing, to derive a data set of 3784
alternative exons in 2250 genes (Supplementary Table S2).
Validation of computationally predicted alternative
Table 1. GO terms enriched in alternatively spliced erythroblast genes
Rank GO term Description P-value FDR q-value
1 GO:0044260 Cellular macromolecule metabolic process 1.74E-11 1.57E-07
2 GO:0006996 Organelle organization 1.73E-10 7.84E-07
3 GO:0022402 Cell cycle process 4.01E-09 1.21E-05
6 GO:0016043 Cellular component organization 5.48E-08 8.27E-05
8 GO:0016568 Chromatin modiﬁcation 1.41E-07 1.60E-04
10 GO:0006325 Chromatin organization 1.61E-07 1.46E-04
12 GO:0007049 Cell cycle 5.63E-07 4.25E-04
13 GO:0080090 Regulation of primary metabolic process 7.68E-07 5.35E-04
14 GO:0010468 Regulation of gene expression 8.07E-07 5.22E-04
15 GO:0044265 Cellular macromolecule catabolic process 9.00E-07 5.43E-04
18 GO:0051276 Chromosome organization 1.37E-06 6.90E-04
19 GO:0000278 Mitotic cell cycle 1.72E-06 8.21E-04
20 GO:0016569 Covalent chromatin modiﬁcation 2.59E-06 1.17E-03
21 GO:0016570 Histone modiﬁcation 2.75E-06 1.19E-03
22 GO:0090304 Nucleic acid metabolic process 2.97E-06 1.22E-03
23 GO:0048285 Organelle ﬁssion 3.84E-06 1.51E-03
30 GO:0000279 M phase 7.27E-06 2.19E-03
33 GO:0010467 Gene expression 1.07E-05 2.94E-03
34 GO:0000086 G2/M transition of mitotic cell cycle 1.14E-05 3.03E-03
35 GO:0000226 Microtubule cytoskeleton organization 1.48E-05 3.81E-03
39 GO:0006511 Ubiquitin-dependent protein catabolic process 1.86E-05 4.32E-03
45 GO:0016070 RNA metabolic process 2.48E-05 4.98E-03
50 GO:0016573 Histone acetylation 2.86E-05 5.18E-03
56 GO:0000280 Nuclear division 5.01E-05 8.09E-03
57 GO:0007067 Mitosis 5.01E-05 7.95E-03
58 GO:0044772 Mitotic cell cycle phase transition 5.27E-05 8.22E-03
60 GO:0000090 Mitotic anaphase 5.67E-05 8.55E-03
62 GO:0051301 Cell division 8.95E-05 1.31E-02
67 GO:0070925 Organelle assembly 1.25E-04 1.69E-02
76 GO:0043484 Regulation of RNA splicing 1.90E-04 2.27E-02
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splicing events was performed by manual inspection of
RNA-seq reads mapped to the human genome and
by RT-PCR analysis of the relevant transcript regions.
Figure 3 illustrates representative alternative splicing
events in genes involved in transcriptional regulation
(NFE2L1, MEF2D, SOX6, ATRX, FOXM1, MAX),
DNA and histone modiﬁcations (DNMT1, MBD1,
CARM1, KDM4B) and signal transduction pathways
(MAP2K7, MAP3K3, MAP3K7). The majority of these
alternative exons did not substantially alter their splicing
efﬁciency between proEs and orthoEs; i.e. similar results
were observed by computational and experimental ana-
lyses independent of differentiation stage. However, alter-
native exons in NFE2L1, MEF2D and CARM1 were
among those observed to splice differently as the cells
matured (discussed below in Figure 4). Of interest,
SOX6 and ATRX are important regulators of globin
gene expression (27–29). These results demonstrate that
differentiating erythroblasts execute an extensive alterna-
tive splicing program that can regulate protein structure
and function via control of pre-mRNA splicing;
moreover, when the affected proteins are transcription
factors, important secondary effects on transcript levels
of other genes might amplify downstream cellular
consequences.
To investigate more broadly which biological processes
are impacted by the erythroid splicing program, we per-
formed GO analysis. GO terms signiﬁcantly enriched
among genes expressing major alternative splicing
events, relative to all genes expressed (above the lowest
quartile) in erythroblasts, are shown in Table 1. The top
terms included numerous descriptors associated with chro-
matin structure and function, cell cycle regulation, organ-
elle organization and regulation of RNA splicing. Among
the read-validated alternative splicing events, we found at
least 24 differentially expressed exons in 22 genes encoding
enzymes that participate in histone modiﬁcations (30)
(Supplementary Table S5), and at least 65 high-conﬁdence
alternative splicing events were detected in 48 genes
encoding RNA binding proteins (Supplementary
Table S6). As indicated in the tables, many of these alter-
native splicing events are not annotated among Refseq
transcripts, and 40% are predicted to introduce PTCs
that induce NMD. All of these splicing events passed low-
expression and low-alternative splicing ﬁlters, and all were
validated by RNA-seq read mapping. These observations
suggest a high level of complexity in regulation of
Construct 15 RNA-seq libraries 
(biological triplicates of 5 stages)
RNA-seq analysis
100’s of millions of 50nt reads
Map reads to the Ensembl transcriptome
Analyze gene level expression and exon inclusion/exclusion   
3784 ‘major’ alternative exons
(low abundance events filtered)
50,000+ candidate alternative splicing events
Validations
Culture CD34+ cord blood erythroid cells
FACS purification of 5 populations: proE, early 
basoE, late basoE, polyE, and orthoE
Figure 2. Flow chart showing the process by which major alternative
splicing events were detected in discrete populations of erythroblasts at
speciﬁc stages of their terminal differentiation.
Figure 3. RT-PCR validation of alternative splicing events in human
erythroblasts. Shown are ampliﬁcation products containing (ﬁlled
circles) or lacking (empty circles) alternative exons ampliﬁed from
erythroblast transcripts. Gene names are indicated above each lane.
Pro Early baso Late baso Poly Ortho
Figure 1. Morphology of differentiation stage-speciﬁc erythroblast populations puriﬁed by FACS as described previously (18).
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erythroid gene expression, and a strong potential that
these splicing events have downstream effects on the abun-
dance and structure of transcripts of numerous other
genes. Thus, important biological pathways express a
rich transcript diversity during late erythropoiesis.
Stage-speciﬁc switches in alternative splicing remodel the
transcriptome during late erythroid differentiation
Alternative splicing switches can play key roles during
differentiation and development by selective up- or
downregulation of individual exons that alter function of
the encoded protein(s). To determine the extent of splicing
transitions during erythroid differentiation, we ﬁrst
compared PSI values for alternative exons in early
(proE) and late (orthoE) erythroblast populations. In all,
1166 exons for which the difference in PSI values (PSI)
exceeded 10% were identiﬁed by this approach; 266 of
these exhibited PSI values exceeding 25%. A subset of
splicing switches that alter protein coding domains was
validated by RT-PCR using primers in the ﬂanking con-
stitutive exons (Figure 4). The previously described switch
in protein 4.1R (EPB41) pre-mRNA splicing served as a
positive control; as expected, splicing of exon 16 exhibited
a substantial increase in PSI in orthoE cells compared with
a much lower splicing efﬁciency in proE (Figure 4A).
Similar to 4.1R, many of the newly discovered switches
involve upregulation of splicing in orthoE (Figure 4A),
but examples of downregulation (Figure 4B) and
switching between mutually exclusive exons (Figure 4C)
were also observed. For some of these, e.g. NDEL1,
USO1, MEF2D and MTMR3, the ‘new’ isoforms with
potentially new functions can be generated in orthoE
CARM1
MTMR3*
NDEL1
MEF2D* USO1
EPB41 DMTN NFE2L1NEK1
LGALS9MARK2
41 395 47
30 526 52
19 26 14 61
27 6628 7020 59 30 64
21 55
H2AFY
25 60
63 22
HSF2
2369
HPS1 PICALM*
28 44 50 59
BNIP2
28 70
AXIN1
28 70
Differentiation-associated 
PSI increase
orthoE
proE
orthoE
proE
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proE
Differentiation-associated 
PSI decrease
Differentiation-associated switch 
of mutually exclusive exons
A
B C
PSI:
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PSI: PSI:
stage: P O P O P O P O P O P O P O
gene:
P O P O P O P O P O P O P OP Ostage:
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Figure 4. Differentiation stage-speciﬁc alternative splicing switches in human erythroblasts. (A) Alternative exons that exhibit stage-speciﬁc
upregulation in splicing efﬁciency. Gels show splicing changes assessed by RT-PCR using primers located in ﬂanking constitutive exons.
Ampliﬁcation products from proE RNA and orthoE RNA are shown in the left and right lanes, respectively. Gene name is indicated above
each gel, while the calculated PSI is shown below each lane. Arrowheads indicate exon inclusion products. Asterisk indicates genes for which
PCR results indicate larger splicing changes than were predicted bioinformatically. (B) Alternative splicing event that exhibits a differentiation-
associated decrease in PSI as cell matures. (C) A differentiation-associated switch involving mutually exclusive exons of 100 and 91 nt, respectively.
The size difference allows electrophoretic separation of the alternative products.
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that were absent or poorly expressed in proE. Except for
USO1, PICALM1 and LGALS9, most of the genes with
upregulated coding exons were also upregulated at the
gene expression level, relative to global gene expression
levels, further supporting the idea that the new isoforms
might play important functions in late erythroblasts.
Consistent with a role for alternative splicing in import-
ant erythroid pathways, several validated switches in
alternative splicing map to genes that function in cytoskel-
etal organization, cell division and chromatin function
(Table 2). One of the biggest switches occurred in the
NDEL1 (nuclear distribution factor E-homolog-like1)
gene that is important for nuclear migration and
nucleokinesis (31), while a less dramatic switch was pre-
dicted in survivin (BIRC5), a cytokinesis factor with a
novel role in erythroblast enucleation (32,33). In the
H2AFY gene, relative expression of mutually exclusive
100- and 91-nt exons reversed almost completely
between proE and orthoE (Figure 4A). This switch
alters the structure and function of the modiﬁed histone,
macroH2A1, which can replace the canonical H2A to gen-
erate functional differences in chromatin activity (34–36).
Consistent with the H2AFY splicing switch in terminal
erythroid differentiation, differences in the relative abun-
dance of the two isoforms have been reported in other
tissues rich in proliferating versus differentiating cells
(37). Other switches of likely functional importance
occurred in kinases having roles in chromosome segrega-
tion and cytokinesis [NEK1, (38–40)] and microtubule-
and actin-based cytoskeletal networks [MARK2, (41)]
in a clathrin assembly gene (PICALM) associated with
anemia and iron metabolism abnormalities in mouse
mutants (42,43); and the mitotic assembly protein
NUMA1.
To explore the hypothesis that alternative splicing
networks can impact erythroblast remodeling, we
examined the differentiation stage-speciﬁcity of splicing
transitions. PSI as a function of erythroblast stage is
shown in Figure 5A for several PCR-validated alternative
exons that exhibited substantially increased inclusion
between proE and orthoE (PSI values 34). For these
genes, most of the change in alternative splicing occurred
in the last two (most mature) erythroblast populations,
although lesser transitions in splicing efﬁciency occurred
at earlier stages. Extending the analysis to the broader set
of alternative exons, we next determined PSI values
across each of the four-stage transitions: proE to early
basoE, early to late basoE, late basoE to polyE and
polyE to orthoE. Figure 5B shows that 155 stage-
speciﬁc splicing switches with PSI> 25 were identiﬁed
in these cultures, and the great majority of these
occurred during the last two cell divisions. Of note, this
is a conservative estimate that counts only exons having
PSI values between 5 and 95 in all 15 samples assayed.
These results demonstrate that most splicing transitions
occur in late erythroblasts, temporally correlated with ex-
tensive cellular remodeling as the cells prepare to enucle-
ate, and supporting the hypothesis that splicing changes
play a determinative role in promoting late erythroid
differentiation.
Alternative splicing coupled to NMD regulates expression
of selected RNA processing factors
Alternative splicing coupled to NMD (AS-NMD) can
regulate gene expression by splicing-mediated introduc-
tion of PTCs that induce nonsense-mediated degradation
of the affected transcripts. PTC-containing transcripts
can be generated by inclusion of exons that encode stop
codons or alter translational reading frame (PTC-upon-
exon inclusion), or by exon skipping events that alter
reading frame (PTC-upon-exon skipping). Having noted
that a number of RNA binding proteins express PTC tran-
scripts in erythroblasts (Supplementary Table S4), we won-
dered whether AS-NMD was functioning to maintain
Table 2. Alternative splicing switches that alter coding domains
gene Exon size PSI (proE to orthoE) Gene function (biological process)
EPB41 63 +50 Cortical actin cytoskeleton
EPB49 66 +34 Actin cytoskeleton organization
NDEL1 35 +46 Centrosome localization
NEK1 132 +42 Cell division; mitosis
NUMA1 42 18 Establishment of mitotic spindle orientation
BIRC5 69 +11 Cell division; cytokinesis
MARK2 162 +34 Regulation of cytoskeleton organization; protein serine/threonine kinase activity
MTMR3 27 2a Peptidyl-tyrosine dephosphorylation; phosphatidylinositol dephosphorylation
CARM1 69 +22 Methyltransferase activity
NFE2L1 90 +39 Sequence-speciﬁc DNA binding transcription factor activity
H2AFY 100b 41 Chromatin modiﬁcation
H2AFY 91b +35 Chromatin modiﬁcation
MEF2D 24 +7a Regulation of transcription from RNA polymerase II promoter
PICALM 24 +9a Clathrin coat assembly; hemopoiesis
BNIP2 36 +27 Apoptotic process
USO1 21 +42 Intracellular protein transport
HPS1 99 +16 Lysosome organization
LGALS9 96 +47 Carbohydrate binding
aRead map data and RT-PCR indicate stronger switch than predicted by computational analysis.
bMutually exclusive exons.
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homeostatic control of expression as described in previous
studies (44–46). Instead, PSI and gene expression data
indicated a different situation characterized by substantial
stage-speciﬁc changes in relative expression of PTC
transcripts (Figure 6). Increased proportions of PTC-
containing transcript isoforms were expressed in late
erythroblasts by either increases in exon inclusion or by
increases in exon skipping (Figure 6A). Many of the pre-
dicted increases are substantial; e.g. the SNRNP70 gene
switches from PSI=13 to PSI=43 for the smaller PTC-
upon-inclusion exon. Similarly, well-known AS-NMD
targets in the SR protein family including SRSF2,
SRSF3, SRSF6 and SRSF7 also showed large PSI
switches from proE to orthoE (PSI values of +12 to
+47). Other classes of AS-NMD candidates include
hnRNP proteins (D, L, LL and M), small nuclear ribo-
nucleic particle proteins (SNRPA1, SNRNP70 and
U2AF1), alternative splicing regulators [TRA2A (45),
TRA2B] and a 3’ processing factor (CPSF4). In a few
cases, an increased proportion of PTC transcripts in late
erythroblasts can occur in the context of PTC-upon-exon
skipping events (Figure 6A, lower panel). SNRPA1, for
example, expressed mainly full-length transcripts in proE
as indicated by PSI=94, but the decrease to PSI=53 in
orthoE predicts substantial expression of PTC isoforms in
orthoE. However, it is important to note that some known
[SRSF11, SNRPB, (45)] or candidate (TIAL1 and
HNRNPD) PTC splicing events showed no evidence of
stage-speciﬁc regulation (Figure 6B, upper panel), and a
few (RHD, BCL2L12, CLK1 and CLK4) were regulated
so as to decrease the proportion of PTC isoforms in
orthoE (Figure 6B, lower panel). RT-PCR validation of
splicing switches involving PTC exons enriched in orthoE
or proE is provided in Figure 7. We propose that splicing-
mediated generation of non-productive (PTC-containing)
transcripts is an important post-transcriptional regulatory
mechanism for controlling a selected subset of RNA
processing factors in late-stage erythroblasts.
In principle, elevated expression of PTC transcripts
could be due to increased production (splicing regulation)
or to decreased degradation (NMD regulation). We
reasoned that simple loss of NMD activity could not
explain maturation-associated increases in PTC exons, as
only selected PTC exons were upregulated in orthoE and a
few were actually downregulated in these cells. This
hypothesis was investigated experimentally by assaying
whether inhibition of NMD could affect steady-state
levels of PTC exons. If NMD is active in normal
orthoE, then steady-state PSI values for PTC exons
should increase due to selective stabilization of these tran-
scripts in cycloheximide-treated erythroblasts inhibited for
NMD. Figure 8 shows that PTC-upon-inclusion exons in
SNRNP70 and HNRPLL had substantially elevated PSI
values in NMD-inhibited cells, with PSI of a 72-nt exon in
SNRNP70 increasing moderately in proE-enriched day 9
erythroblasts and dramatically in orthoE-enriched day 16
erythroblasts (upper panel). NMD inhibition also
increased the proportion of PTC transcripts from the
BCL1L12 and CLK4 genes that were generated by exon
skipping and were more enriched in proEs (Figure 8, lower
panel). We conclude that the NMD machinery is still
active in late erythroblasts and therefore that the accumu-
lation of PTC isoforms in these normal cells is not primar-
ily due to loss of NMD, but instead must be due, at least
in part, to regulation at the level of alternative splicing.
Moreover, as the ‘missing’ quantity of PTC isoforms in
normal cells must have been degraded, we propose that
alternative splicing coupled to NMD (AS-NMD) is a
mechanism for downregulating gene expression in late
erythroblasts, analogous to the intron retention mechan-
ism used by late-stage granulocytes to downregulate
selected genes (47). Consistent with this, 9 of 11 RBP
genes with upregulated PTC events (82%) were
downregulated at the gene expression level relative to
total mRNAs in late erythroblasts. In contrast, among
genes shown in Figure 4 with validated upregulation of
non-PTC exons in orthoE, 12 of 15 genes (80%) exhibited
increases in gene expression level.
DISCUSSION
The erythroblast system provides a unique opportunity to
study the role of post-transcriptional RNA processing in a
differentiation stage-speciﬁc manner during the extensive
cellular remodeling that characterizes terminal differenti-
ation. We found a robust alternative splicing program
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enriched in genes that function in cell cycle regulation,
organelle organization, chromatin structure and function
and RNA processing, all of which undergo tremendous
changes before enucleation. Most importantly, dynamic
switches in alternative exon usage remodel the late eryth-
roid transcriptome so as to generate new mRNA isoforms
or to alter proportions of existing isoforms. These data
support the hypothesis that a highly structured alternative
splicing program is executed during terminal erythroid
differentiation to regulate key biological processes as the
cells prepare to enucleate and form mature red cells.
Previously, proper alternative splicing of protein 4.1
(EPB41) pre-mRNA was shown to be essential for
generating a red cell membrane with the specialized mech-
anical properties required for survival in the circulation
(48). The ﬁnding of abundant alternative splicing events
in erythroblasts suggests many additional contributions to
erythroid-speciﬁc functions. For example, regulators of
alpha- and beta-globin gene expression such as ATRX
and its interacting partners MECP2 and macroH2A1, as
well as BCL11A and SOX6 all express multiple transcript
isoforms whose importance has not been sufﬁciently
evaluated. The GO categories enriched in alternative
splicing events suggest additional roles in regulation of
chromatin condensation, autophagy and enucleation in
late erythroblasts, all key and unique events during late
stages of terminal erythroid differentiation. We anticipate
that some of these alternative splicing switches might be
shared by other cell types undergoing the transition from
proliferation to terminal differentiation; e.g. differences in
relative abundance of H2AFY isoforms in tissues rich in
proliferating versus differentiating cells (37) mirror the
changes observed in erythroblasts. The erythroid differen-
tiation system may be ideal for studying such splicing
events.
Our studies suggest that a second major function for the
erythroid alternative splicing program is post-transcrip-
tional downregulation of gene expression in erythroblasts.
We hypothesize that NMD-associated splicing switches,
similar to switches in coding exons, are driven by
changes in expression of splicing regulatory proteins
during terminal erythroid differentiation that can up- or
downregulate expression of PTC exons, according to
physiological requirements for the encoded proteins. The
marked changes in steady-state levels of PTC-containing
transcripts during differentiation indicate that the mech-
anism regulating their production must be distinct from
homeostatic (often autoregulatory) control mechanisms
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previously ascribed to AS-NMD [(49) and references
therein]. By maintaining active machinery for both alter-
native splicing and NMD, erythroblasts could coordinate
these processes to limit expression in proliferating proE
of differentiation functions required for remodeling in
orthoE, while also downregulating in orthoE proliferative
functions not needed in late erythroblasts. Differentiation-
associated switches in PTC exons have already been
proposed to operate in differentiating neurons, as, for
example, changes in expression of splicing factor PTB
can regulate switches in both PTC and non-PTC splicing
events (50,51). The full impact of such pathways on eryth-
roid biology may extend well beyond RNA binding
proteins, as a substantial fraction of alternative splicing
events affecting histone modifying enzymes (42%,
Supplementary Table S1) and many DNA binding
proteins (results not shown) were predicted to induce
NMD. Moreover, the current study likely underestimated
or entirely missed PTC splicing switches that generate
rapidly degraded transcripts, or splicing switches that
resulted in retained introns; the latter occurs during late
stages of granulocyte differentiation where they can
suppress expression of selected genes (47). In fact, inspec-
tion of RNA reads mapping to the SF3B1 gene re-
vealed increasing abundance of an intron retention event
in late-stage erythroblasts (results not shown) that predicts
reduced expression of this critical splicing factor
implicated in myelodysplasia (4,52). Future studies will
explore these potential expansions of AS-NMD by
RNA-seq analysis of NMD-inhibited erythroblasts.
In conclusion, coordinated temporal control of alterna-
tive splicing plays a critical role in regulating structure and
function of the erythroid transcriptome, likely having a
major impact on orderly differentiation of erythroblasts.
Analogous cell type-speciﬁc or differentiation-associated
alternative splicing programs that are critical for cell
identity have been identiﬁed in non-erythroid cell types
including neurons, muscle cells, epithelial cells and
T lymphocytes (3,53–55). Conversely, abnormal splicing
factor expression as a consequence of human genetic
disease or as a result of genetic knockdown in model or-
ganisms can profoundly alter splicing networks and have
adverse phenotypic effects. Disturbance of programmed
splicing networks underlies many complex human
genetic diseases including myotonic dystrophy, the auto-
immune neurologic disease paraneoplastic opsoclonus-
myoclonus ataxia, facioscapulohumeral muscular
dystrophy and amyotrophic lateral sclerosis (53,56–59).
Moreover, a number of hematological cancers including
myelodysplasia can be caused by mutations in splicing
factor genes (4,52,60,61), and it has been shown that
erythroblasts from myelodysplasia patients exhibit dis-
ordered erythropoiesis (62). Understanding the erythro-
blast splicing program will provide new insights into
normal differentiation mechanisms and also into dis-
ordered differentiation in disease states.
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